Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Open Clinical Trials

August 2025

To refer a patient, please directly contact the disease specific nurse navigator.

Please note that in early phase studies, enrollment slots change often and may be limited.

For more information regarding trials at the University of Colorado, please visit:
https://researchstudies.cuanschutz.edu/

Jump to Cancer Types

Common Eligibility Criteria for Clinical Trials

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

Satellite Site Contacts

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Sara Johnson, BSN, RN	Sara.johnson@uchealth.org	Phone: 720-848-9237 Fax: 720-848-1774
Physician Leads	**Email**	**Phone**
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	

Metastatic Breast Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
PRE-I-SPY Phase 1/1b Platform, PRE-Investigation of Serial Studies	Previously treated metastatic breast cancer	NCT05868226	AMC
Phase 3 trial of Saruparib plus Camizestrant vs MD choice of CDK4/6 plus endocrine therapy	ER+, HER2-, BRCA1, BRCA2 or PALB2 mutations	NCT06380751	AMC
Phase 3 Study of MK-2870 +/- pembromizumab vs physician's choice therapy	HR+/HER2-negative metastatic breast cancer	NCT06312176	AMC CCMC HRH
Phase 2 trial of nab-paclitaxel, durvalumab, tremelimumab +/- vaccine	1L metastatic TNBC	NCT03606967	AMC
Phase 2 study of tucatinib, eribulin, trastuzumab	Previously treated metastatic HER2+ breast cancer	NCT05458674	AMC
PIKture-01 Phase 1 OKI-219 (mutant selective PI3K H1047R inhibitor)	Previously treated metastatic solid tumors with PI3K H1047R mutation	NCT06239467	AMC
Phase 1 study of XMT-2056 (immune conjugate). *This trial requires hospitalization and inpatient delivery of study drug for some cycles*	Previously treated metastatic HER2+ breast or Gastric/GE	NCT05514717	AMC
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi)	1L metastatic HR+HER2- breast cancer	NCT04862663	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor)	Metastatic HR+HER2- breast cancer with PI3K mutation	NCT05768139	AMC (POEMs)
Phase 3 study OP-1250 (SERD)	Metastatic HR+HER2-	NCT06016738	AMC, HRH, CCMC, LT
Phase 3 study of zanidatamab + standard therapy v. trastuzumab + standard therapy	Previously treated metastatic HER2+ breast cancer	NCT06435429	AMC, HRH, CCMC
DYNASTY-Breast02: Phase 3 DB-1303 (ADC) v. standard therapy	Metastatic HR+ HER2 low	NCT06018337	AMC, LT, HRH, CCMC
Phase 2 study of alisertib + endocrine therapy	Metastatic HR+HER2-	NCT06369285	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	NCT06233942	AMC (POEMs)
CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	Metastatic breast cancer in older adults	NCT06377852	AMC

Early-Stage Breast Cancer			
ISPY2.2 Neoadjuvant study	Stage II-III Breast cancer	NCT01042379	AMC, LT, HRH, CCMC
EMBER-4: Adjuvant imlunestrant v standard therapy	High risk HR+HER2- 2-5 years endocrine therapy	NCT05514054	AMC, LT, HRH
DARE: Phase 2 trial of ctDNA-guided treatment	High risk HR+HER2-	NCT04567420	AMC, LT, HRH, CCMC
OFSET: Phase 3 study of chemotherapy + ovarian suppression	Premenopausal HR+HER2- breast cancer	NCT05879926	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR	TNBC with pCR to neoadjuvant therapy	NCT05812807	AMC, LT, HRH
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer	Low-risk node+ or T3N0M0 breast cancer following surgery	NCT03488693	AMC, CCMC, HRH, LT (RT Group)
NRG-BR007: DEBRA: Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer	Stage I, HR+, HER2- breast cancer with Oncotype RS ≤ 18	NCT04852887	AMC, CCMC, HRH (RT Group)
NRG-BR008: HERO: Phase 3 trial of optimized RT in low-risk HER2+ breast cancer	Early stage HER2+ breast cancer following surgery	NCT05705401	AMC, HRH (RT Group)
S2206: Phase 3 trial of Druvalumab plus chemo vs chemo alone	MammaPrint ultrahigh ER/PR+, HER2-	NCT06058377	AMC, LT, HRH, CCMC
CAMBRIA-2: Phase 3 trial of Camizestrant vs standard endocrine therapy	ER+/HER2-; intermediate-high or high risk for recurrence following definitve treatment, currently NED	NCT05952557	AMC, HRC, CCMC
A Phase 1b study of Psilocybin Assisted Psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	NCT06430541	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Cutaneous Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Nurse navigator	melanoma@uchealth.org	Phone: 720-848-0505 Fax: 720-848-0614
Physician	**Email**	**Phone**
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	

High-Risk Resected Melanoma			
Study Name	**Patients**	**NCT#**	**Sites**
Phase 2 study of pembrolizumab +/- mRNA-4157 (personalized cancer vaccine)	High-risk melanoma after complete resection	NCT03897881	AMC
Advanced Melanoma			
Phase 2/3 study of LNS8801 with and without Pembrolizumab	Treatment Refractory, Unresectable Melanoma	NCT06624644	AMC
Phase 3 trial of Lifileucel (LN-144 Tumor infiltrating lymphocyte) with Pembro vs Pembro monotherapy	Untreated, Unresectable or metastatic melamoma	NCT05727904	AMC
IGNYTE-3: Phase 3 trial of Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice	Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen	NCT06264180	AMC
Phase 3 trial of fianlimab and cemiplimab vs reoatlimab and novolumab	Unresectable or metastatic melanoma	NCT06246916	AMC
PRISM-MEL-301: Phase 3 trial of nivolumab +/- IMC-F106C (PRAME x CD3 bispecific)	1L advanced melanoma HLA-A*02:01-positive	NCT06112314	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	NCT05355701	AMC (POEMs)
Phase 1 study of DCSZ11 (anti-CD93)+/- pembro in advanced solid tumors	Previously treated metastatic melanoma	NCT05785754	AMC (POEMs)
Uveal Melanoma			
DAR-UM-2: Darovasertib (PKCi) + crizotinib v. standard therapy	1L HLA-A2 negative metastatic uveal melanoma	NCT05987332	AMC
Mekel Cell Carcinoma			
MATRiX: Phase 2 trial of ATR inhibition	Refractory Merkel cell Carcinoma	NCT05947500	AMC
Advanced Cutaneous Malignancies in Transplant Recipients			
Phase 1B/2 study of RP1 (oncolytic IO)	Solid organ or hematopoietic cell transplant recipient	NCT04349436	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Gastrointestinal Oncology Anschutz Medical Campus (AMC)		
Nurse Navigators	**Email**	**Phone**
Jamie Peterson	Jamie.Peterson@uchealth.org	Phone: 720-848-2636
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Sarah Reynolds	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physicians	**Email**	**Phone**
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	

Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers			
Phase 3 study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab (ARTEMIDE-Gastric01)	1L HER2 Gastric Cancer	NCT06764875	AMC
Phase 2 study of induction SBRT and olaparib followed by pembrolizumab olaparib for gastric and GEJ cancers	2L+ with homologous recombination deficiency mutation	NCT05379972	AMC, HRH
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 2 study of induction FLOT followed by neoadjuvant chemoRT in resectable adenocarcinoma esophagus or GEJ	Newly diagnosed, resectable T3-4 or node+ adenocarcinoma esophagus or GEJ	NCT04028167	AMC
EDDC: Phase 1 study using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	NCT05701527	AMC (POEMs)
Phase 1 study of TJ033721 in metastatic gastric, GE and esophageal adenocarcinoma	1L metastatic gastric, GE, and esophageal adenoca positive for CLDN18.2	NCT04900818	AMC
Early-Stage Colorectal Cancer (CRC)			
CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease	Stage IIIA/B MSS colon adenocarcinoma following curative resection	NCT05174169	AMC, LT, HRH, CCMC
Metastatic Colorectal Cancer (CRC)			
Phase I trial of AWN003694 in combination with Cetuximab and Encorafenib	Refractory BRAF V600E Metastatic CRC	NCT06102902	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	NCT06445062	AMC, LT
OrigAMI-3: Phase 3 study of FOLFIRI + amavantamab v cetuximab/bevacizumab in metastatic CRC	2L metastatic CRC KRAS/NRAS and BRAF WT	NCT06750094	AMC

INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	NCT04929223	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. *This trial requires hospitalization and inpatient delivery of study drug for some cycles*	Previously treated metastatic CRC, GCC+, MSS	NCT05319314	AMC
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
AE2222: PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets	Unresectable liver metastatic CRC	NCT05863195	AMC
Phase 1 study of JNJ-89402638 for metastatic CRC	3L+ unresectable metastatic CRC	NCT06663319	AMC
Phase 1 study of BI1831169 +/- ezabenlimab in advanced solid GI tumors	Advanced or metastatic GI tumors with no standard therapies	NCT05155332	AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors	Ewings sarcoma, CRC	NCT03715933	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
Liver Cancer			
Phase Ib/2 study of multiple immunotherapy based treatment combinations	Locally advanced/metastatic /unresectable HCC; no priory treament	NCT04524871	AMC, HRH, CCMC
EMERALD-Y90: Phase 2 study of durvalumab + bevacizumab following transarterial radioembolization	Locoregional hepatocellular carcinoma with no extrahepatic disease	NCT06040099	AMC
Phase 1b/2 study of TTI-101 in advanced or metastatic HCC	1-3L Unresectable, locally advanced or metastatic HCC	NCT05440708	AMC
Biliary Tract Cancer			
Phase 1/2 study of MK-2870 in combination with other anticancer agents	2L Biliary	NCT06428409	AMC, HRH, CCMC
ARTEMIDE-Biliary01: Phase 3 study of rilvegostomig + chemo as adjuvant therapy for biliary tract cancer	Adenocarcinoma of biliary tract following complete resection with curative intent	NCT04995523	AMC, HRH
Phase 2 trial of durvalumab + gemcitabine+cisplatin as neoadjuvant therapy for high-rish resectable intrahepatic cholangiocarcinoma	Intrahepatic cholangio that is considered resectable and high-risk, untreated	NCT04308174	AMC
Phase 1/2 study of M3814 + avelumab with hypofractionated radiation in metastatic hepatobiliary malignancies	2L+ metastatic or locally advanced cholangio or gallbladder carcinoma	NCT04068194	AMC
Pancreatic Cancer			
Phase I/IB trial of radiotherapy in combination with TTI-101 in borderline resectable and locally advanced pancreatic ductal adenocarcinoma	Borderline resectable and locally advanced pancreatic ductal adenocarcinoma	NCT06141031	AMC

Phase 3 study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy	Treatment naive Metastatic pancreatic ductal cancer	NCT06608927	AMC, HRH, CCMC, LT
Intraperitoneal Paclitaxel for Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinamatosis	NCT07030283	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	NCT06445062	AMC, LT
Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	NCT04172532	AMC
S2001: Phase 2 study of Olaparib +/- pembrolizumab maintenance in metastatic pancreatic ca with germline BRCA1/2 mutation	Metastatic pancreatic cancer with germline BRCA1/2 mutation and prior response to platinum-based chemo	NCT04548752	AMC, HRH
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
EDDC: Phase 1 study using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	NCT05701527	AMC (POEMs)
Phase 1b study of ATP150/2 (vaccine), VSV-GP154 (viral vector) and ezabenlimab (ICI) in pancreatic cancer	Metastatic pancreatic ductal adenocarcinoma KRAS G12D/G12V mutation	NCT05846516	AMC
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer	2-3L metastatic or unresectable pancreatic ductal adeno	NCT05685602	AMC
Neuroendocrine Cancers			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	NCT04919226	AMC
NET Retreat: Phase 2 study of 177Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine	Metastatic grade 1/2 midgut neuroendocrine tumors	NCT05773274	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Genitourinary Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
Physician	**Email**	**Phone**
Thomas Flaig, MD	Thomas.flaig@cuanschutz.edu	
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	

Localized Prostate Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
Poten-C for intermediate risk	Intermediate risk prostate cancer	NCT03525262	AMC
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations	Localized prostate cancer with germline BRCA1/2 mutation	NCT05806515	AMC
NRG GU010: Genomic risk stratification for unfavorable intermed risk localized prostate cancer	Localized prostate cancer unfavorable intermediate risk	NCT05050084	AMC (RT Group)
Pragmatic study of metformin v. lifestyle mods	Localized prostate cancer	NCT05515978	AMC
PREDICT-RT (NRG-GU009): Phase 3 trial of de-intensification for low genomic risk and intensification for high genomic risk	High-risk prostate cancer	NCT04513717	AMC, HRH (RT Group)
Phase 4 study of PYLARIFY PET/CT or PET/MRI	Newly diagnosed, favorable intermediate risk	NCT06074510	AMC
Metastatic Prostate Cancer			
S1802: SST +/- surgery or radiation	Metastatic hormone sensitive prostate cancer	NCT03678025	AMC
NRG GU011:PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy	Oligometastatic hormone sensitive prostate cancer	NCT05053152	AMC, HRH (RT Group)
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro	De novo and treatment emergent neuroendocrine/small cell prostate cancer	NCT02861573	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	NCT06136624	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	NCT06136650	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343	Metastatic hormone refractory docetaxel refractory prostate cancer	NCT06095089	AMC
Phase 1b/2a study of Pocenbrodib alone or in combination with Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617	Metastatic castration-resistant Prostate Cancer	NCT06785636	AMC

Bladder Cancer			
Phase 2 study of intravesiclar instillation of TARA-002	High grade Non-muscle invasive bladder cancer	NCT05085990	AMC
EA8192 Preoperative durvalumab and/or chemo	Upper tract bladder cancer	NCT04628767	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance	Muscle invasive bladder cancer after surgery	NCT05987241	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors	2L metastatic bladder cancer	NCT03375307	AMC
ETCTN 10483: FGFR2/3 genetic alterations erdafitinib + EV	2L metastatic bladder cancer	NCT04963153	AMC, LT, HRH
S1937: Eribulin + gemcitabine v. standard therapy	3L+ metastatic bladder cancer post PD1i	NCT04579224	AMC
MoonRISe-1: Phase 3 study of TAR-210 v. single agent intravesical chemotherapy for bladder cancer	Intermediate-risk non-muscle invasive bladder cancer + FGFR alterations	NCT06319820	AMC
Kidney Cancer			
SAMURAI: Phase 2 study of SABR in patients receiving immunotherapy	Metastatic unresectable Renal Cell carcinoma	NCT05327686	AMC, LT, HRH, CCMC
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus	Neoadjuvant therapy for RCC with tumor thrombus	NCT05969496	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors	2L metastatic bladder cancer	NCT03375307	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC	2L+ metastatic clear cell RCC	NCT06234605	AMC
Penile Cancer			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND	Penile cancer	NCT02305654	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Gynecologic Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Clinic schedulers	-	Phone: 303-724-2066
Physician	**Email**	**Phone**
Brad Corr, MD	Bradley.corr@cuanschutz.edu	

Ovarian Cancer – Frontline			
Study	**Patients**	**NCT#**	**Sites**
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	NCT05659381	AMC
Ovarian Cancer – Maintenance			
GOG 3072 TETON: Phase 1b study of ZN-c3 (Wee1i) + chemo or bevacizumab in ovarian cancer	1-2L platinum sensitive ovarian, primary peritoneal, fallopian tube cancer no BRCA mutation	NCT04516447	AMC
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	NCT05887609	AMC
Ovarian Cancer – Recurrent			
Phase 1/2a study of AZD5335 (ADC folate receptor + TOP1i) in solid tumors	Platinum-resistant or platinum-sensitive ovarian cancer	NCT05797168	AMC
Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	NCT05902988	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	NCT06233942	AMC (POEMs)
Phase I study of IMGN151 (anti-FRa ADC) in ovarian cancer	Recurrent endometrial or high-grade serous epithelial ovarian cancer	NCT05527184	AMC
A Phase 1b study of Psilocybin Assisted Psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	NCT06430541	AMC
Ovarian Cancer – Low Grade			
ComboMATCH: Palbociclib and binimetinib in RAS-mutant cancers	Low-grade serous ovarian cancer with RAS mutation	NCT05554367	AMC (POEMs)
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with	HRD tumors with prior PARPi use as immediate prior therapy	NCT05327010	AMC (POEMS)

Molecularly-Selected Solid Tumors (ComBET)"			
Endometrial Cancer - Presurgical			
Surgical window of opportunity study of megestrol +/- metformin for endometrial intraepithelial neoplasia	Endometrial intraepithelial neoplasia no prior therapy	NCT04576104	AMC
Endometrial Cancer - Frontline			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- Hylecta or Phesgo in HER2+ Endometrial cancer	1L Stage I-IV endometrial serous carcinoma or carcinoma HER2+	NCT05256225	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early stage endometrial cancer	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	NCT06388018	AMC
Endometrial Cancer - Recurrent			
GOG 3104: Phase 3 study of sacituzumab govitecan v. standard therapy in previously treated endometrial cancer	Recurrent or persistent endometrial cancer previously treated with platinum and immunotherapy (up to 4L)	NCT06486441	AMC
Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	NCT05902988	AMC
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/-gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivon oncosignature	Up to 4L: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivol Oncosignature Status	NCT05548296	AMC
Study of E7386 in combination with other anticancer drugs in solid tumors	Reurrent or persistent endometrial cancer previously treated with platinum and immunotherapy	NCT04008797	AMC
Phase I study of IMGN151 (anti-FRa ADC) in ovarian cancer	Recurrent endometrial or high-grade serous epithelial ovarian cancer	NCT05527184	AMC
Uterine Leiomyosarcoma			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma	Newly diagnosed ER+ uterine leiomyosarcoma	NCT05649956	AMC, HRH
BRCA Mutation Carriers			
SOROC: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	NCT04251052	AMC, HRH

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Head and Neck Cancer Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Jamie Peterson	Jamie.Peterson@uchealth.org	Phone: 720-848-2636
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Physician	**Email**	**Phone**
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

Head and Neck Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
Phase 1b/2 study of NT219 in combination with Pembro or Cetuximab	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	NCT06919666	AMC, HRH
FORTIFI-HN010: Phase 2/3 study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab	First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT06788990	AMC
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC	Unresected locally advanced head and neck squamous cell carcinoma (HNSCC) who have not progressed following definitive concurrent chemoRT	NCT06129864	AMC, HRH
OrigAMI-4: Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC	Recurrent or metastatic HNSCC	NCT06385080	AMC
Phase 1 study of BL-B01D1 in metastatic NSCLC, SCLC, Esophageal SCC and HNSCC	Metastatic or unresectable NSCLC, SCLC, Esophageal SCC and HNSCC previously treated	NCT05983432	AMC
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC	locoregionally recurrent refractory or oligometastatic HNSCC	NCT06211335	AMC, HRH
NRG- HN010: Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	NCT05408845	AMC, HRH
Phase 2 study of darolutamide + leuprolide in metastatic AR+ salivary gland cancer	Hormone-therapy naïve recurrent and/or metastatic AR+ salivary gland cancer	NCT05669664	AMC
Phase 3 study of BRAF-targeted therapy v. cabozantinib in RAI-refractory differentiated thyroid cancers with BRAF V600E mutation	Advanced RAI-refractory differentiated thyroid cancers with BRAF V600 E mutation	NCT06475989	AMC, HRH

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Hematology Clinical Trials Unit Anschutz Medical Campus (AMC)		
Nurse Navigator UCH-BDC Intake Team	**Email** UCH-BDCIntakeTeam20181018184924@uchealth.org	**Phone** 720-848-2595
Doc Line		Phone: 720-848-2628 (doc line)
Physician	**Email**	**Phone**
Leukemia: Dan Pollyea, MD	Daniel.pollyea@cuanschutz.edu	
Cell Therapy/Stem Cell Transplant: Jon Gutman, MD	Jonathan.gutman@cuanschutz.edu	
Lymphoma: Manali Kamdar, MD	Manali.kamdar@cuanschutz.edu	
Multiple Myeloma: Dan Sherbenou, MD, PhD	Daniel.sherbenou@cuanschutz.edu	
Benign Heme and MPNs: Brandon McMahan, MD	Brandon.mcmahon@cuanschutz.edu	

Leukemia			
Study	**Patients**	**NCT#**	**Sites**
22-0054: Phase I study of CD19 Directed CAR T Cells in Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission) (PI: Kamdar)	Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2	NCT05535855	AMC
24-0178: Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	NCT06429449	AMC
24-1444: A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos)	Undergoing allogenic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	NCT05473910	AMC
24-0685: A multicenter, open-label, randomized, phase 2 study of venetoclax and Azacitidine plus Cusatuzumab vs. Venetoclax and Azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy (PI: McMahon)	Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts). Previously untreated AML. Deemed unfit for intensive therapy.	NCT06384261	AMC
23-0273: Study of cladribine+venetoclax after failure of	Ages ≥ 18; Relapsed/Refractory AML; ECOG of ≤2	NCT06232655	AMC

venetoclax+hypomethylating agent in monocytic AML (PI: McMahon)			
23-0061 KO-MEN-007: Phase 1 study of Venetoclax/Azacitidine or Venetoclax + Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) + Ziftomenib for AML (PI: McMahon)	Ages ≥ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of ≤2	NCT05735184	AMC
20-2350: Phase 1 study of KPT-9274 in relapsed or refractory AML (PI: Pollyea)	Ages ≥ 18 years; non-APL AML who have not responded to or relapsed after at least one prior therapy and for whom no standard therapy that may provide clinical benefit is available; ECOG of ≤ 2	NCT04914845	AMC
23-2063: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression (PI: McMahon)	Acute leukemia; not eligible for participation in an ongoing clinical study and have no approved treatment options.	NCT05918913	AMC
22-1502: Dose-escalation and dose-expansion Study of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) (PI: Schwartz)	Ages ≥ 18 years; diagnosed R/R B-ALL; B-ALL blast expressing CD22; ECOG of 0 or 1	NCT04150497	AMC
Myelodysplastic Syndrome Trials			
22-0130: A Phase 1 study of INCB057643 in Myelofibrosis and Other Advanced Myeloid Neoplasms (PI: McMahon)	Ages ≥ 18; relapsed or refractory MF, MDS, or MDS/MPN (Part 1); ECOG of ≤2	NCT04279847	AMC
24-1444: A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos)	Undergoing allogenic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	NCT05473910	AMC
Lymphoma			
25-0024: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma (PI: Kamdar)	Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.	NCT06337318	AMC
24-0458: A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-	Ages > 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL	NCT04234048	AMC

Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion (PI: Haverkos)			
24-0139: A Phase III, Multicenter, Randomized Open-label Study Comparing the Efficacy and Safety of Glofitamab in combination with Polatuzumab Vedotin plux Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-Chp) vs. Pola-R-Chp in previously untreated patients with Large B-cell Lymphoma (PI: Kamdar)	Ages 18-80; ECOG of 0, 1, or 2; Previously untreated participants with CD-20 positive Large B-cell Lymphoma	NCT06047080	AMC
22-1252: Phase 2 basket study of MK-2140 as monotherapy and in combination in aggressive and indolent B-cell malignancies (waveLINE-006) (PI: Bair)	Ages ≥ 18; diagnosed aggressive or indolent B-cell malignancies; ECOG of ≤2	NCT05458297	AMC
22-0939: Phase Ib Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar)	Ages ≥ 18; ECOG of ≤2	NCT05169515	AMC
19-3011: Phase 2 study of JCAR017 in adults with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) (PI: Kamdar)	Ages ≥ 18; relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) histologically confirmed < 6 mos of screening, by local pathology; FL: Received at least 1 prior line; MZL: received 2+ prior lines; ECOG of 0 or 1	NCT04245839	AMC
21-2578: Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and adult patients with relapsed and/or refractory B-NHL (PI: Kamdar)	Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	NCT05098613	AMC
Multiple Myeloma			
23-0376: A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial) (PI: Sherbenou)	Ages ≥ 18; Diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1	NCT05722418	AMC
Benign Heme			
22-0305: Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in Polycythemia Vera (PI: McMahon)	Ages ≥ 18; Diagnosed polycythemia vera; ECOG of ≤2	NCT05210790	AMC

22-0130: A Phase 1 study of INCB057643 in Myelofibrosis and Other Advanced Myeloid Neoplasms (PI: McMahon)	Ages ≥ 18; relapsed or refractory MF, MDS, or MDS/MPN (Part 1); ECOG of ≤2	NCT04279847	AMC
Allo Transplant/GVHD			
24-1138: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (PI: Schwartz)	New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy (Jagasia et al 2015).	NCT06388564	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Neuro-Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Clinic scheduler	-	Phone: 720-848-0300
Physician	**Email**	**Phone**
Denise Damek, MD	Denise.damek@cuanschutz.edu	-

Neuro-Oncology			
Study	**Patients**	**NCT#**	**Sites**
Phase I Study of [177Lu] Lu-NeoB in Combination with Radiotherapy and Temozolomide in newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma	Newly diagnosed and recurent GMB	NCT05739942	**A**MC
Phase 1 study of perioperative vorasidenib (IDH1/2i) + pembrolizumab in recurrent or progressive enhancing IDH-1 mutant astrocytomas	IDH1 mutant astrocytomas/oligodendrogliomas recurrent or progressive enhancing	NCT05484622	AMC
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma	Newly diagnosed and recurrent GBM	NCT03970447	AMC,
Phase 1/2 trial of Selinexor (XPO1i) + temozolomide in recurrent glioblastoma	Recurrent GBM	NCT05432804	AMC
Study of SonoCloud-9 + carboplatin v. standard of care in first recurrence GBM	1st Recurrent GBM	NCT05902169	AMC
Phase 1/2 study of nivolumab +/- ipilimumab + multifraction SRS in recurrent high grade radiation-relapsed meningioma	Recurrent grade II/III radiation-relapsed meningioma	NCT03604978	AMC
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	NCT02523014	AMC
Phase 2 study of tirabrutinib (BTKi) in primary CNS lymphoma	Newly diagnosed CNS lymphoma	NCT04947319	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Phase 1, Expansion, Molecular Studies (POEMs) Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
Physician	**Email**	**Phone**
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

POEMs Studies			
Study	**Patients**	**NCT#**	**Sites**
Phase 1/2 study of ATX-559	Locally advanced or metastatic solid tumors and molecularly defined tumors	NCT06625515	AMC
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor)	Advanced solid tumors with SMARCA4/BRG1 Alterations	NCT06561685	AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors	Ewings sarcoma, CRC	NCT03715933	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	NCT05355701	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors	1L NSCLC PD-L1 TPS $\geq$ 50%	NCT05533697	AMC
ComBET: Phase 2 trial of ZEN-3694 (BETi) + talazoparib in advanced solid tumors	Advanced solid tumor prior PARPi +/-DDR (not PARP1/2) mutation	NCT05327010	AMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor)	Metastatic HR+HER2- breast cancer with PI3K mutation	NCT05768139	AMC
Phase 1 study of DCSZ11 (anti-CD93) as monotherapy and combo in advanced solid tumors	Melanoma and others	NCT05785754	AMC
ComboMATCH: Palbociclib and binimetinib in RAS-mutant cancers	Low-grade serous ovarian cancer with RAS mutation	NCT05554367	AMC
Phase 1 study of RMC-6291 (KRAS G12Ci) + RMC-6236 (KRASi) in KRAS G12C mutant solid tumors	Previously treated metastatic NSCLC with KRAS G12C mutation	NCT06128551	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Metastatic breast and ovarian cancer	NCT06233942	AMC
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload)	Select advanced solid tumors	NCT06384352	AMC
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC
Phase 1 study of NX-1607 (CBL-2i)	Select advanced solid tumors	NCT05107674	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Radiation Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Pam Miranda	Pamela.miranda@uchealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	**Email**	**Phone**
Christine Fisher, MD	Christine.fisher@cuanschutz.edu	-
Rachel Rabinovitch, MD	Rachel.Rabinovitch@cuanschutz.edu	-

Radiation Oncology-Breast Cancer			
Study	**Patients**	**NCT#**	**Sites**
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer	Low-risk node+ or T3N0M0 breast cancer following surgery	NCT03488693	AMC, CCMC, HRH, LT
DEBRA (BR007): Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer	Stage I, HR+, HER2- breast cancer with Oncotype RS ≤ 18	NCT04852887	AMC, CCMC, HRH
Radiation Oncology- Genitourinary Cancer			
NRG GU011:PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy	Oligometastatic hormone sensitive prostate cancer	NCT05053152	AMC, HRH
NRG GU010: Genomic risk stratification for unfavorable intermed risk localized prostate cancer	Localized prostate cancer unfavorable intermediate risk	NCT05050084	AMC
Radiation Oncology -Lung Cancer			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung	Small-Cell Lung Cancer	NCT04155034	AMC, HRH
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH
Radiation Oncology-Pancreatic Cancer			
Phase I/IB trial of radiotherapy in combination with TTI-101 in borderline resectable and locally advanced pancreatic ductal adenocarcinoma	Borderline resectable and locally advanced pancreatic ductal adenocarcinoma	NCT06141031	AMC
Radiation Oncology –Neuro Oncology			
Phase I Study of [177Lu] Lu-NeoB in Combination with Radiotherapy and Temozolomide in newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma	Newly diagnosed and recurent GMB	NCT05739942	**A**MC
Radiation Oncology-Multiple Cancer Types			
NRG-BN013: PHASE 3 study of single fraction SRS for versus FSRS for intact brain metastases	Non-small cell lung cancer Melanoma Breast cancer Renal cell carcinoma Gastrointestinal cancer at least 1 and up to 8 total intact brain metastases and at least 1 of the up to 8	NCT06500455	AMC

	lesions must be a lesion with a maximum diameter of >/= 1.0 cm and </= 3.0 cm		

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Sarcoma Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201 Fax: 720-848-0160
Physician	**Email**	**Phone**
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	-

Sarcoma			
Study	**Patients**	**NCT#**	**Sites**
Phase 1 study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin	Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas	NCT05711615	AMC
STRASS 2 (EA7211): Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma	High risk retroperitoneal sarcoma (LPS/LMS)	NCT04031677	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	NCT06422806	AMC
A randomized blinded placebo-controlled phase 2 study of inbrx-109 in unresectable or metastatic conventional chondrosarcoma	Unresectable Metastatic Convention Chondrosarcoma	NCT04950075	AMC
Phase 1/2 st udy of ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated subjects with leiomyosarcoma	Leiomyosarcoma	NCT05712694	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	NCT06127407	AMC
A Phase I/Ib Study of Losartan in Combination with Sunitinib in the Treatment of Pediatric and Adult Patients with Relapsed or Refractory Osteosarcoma	Osteosarcoma	NCT03900793	CHCO, AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Thoracic (Lung) Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Courtney Sorensen, RN	Courtney.thoutt@uchealth.org	Phone: 720-848-2962 Fax: 720-848-0360
Physician	**Email**	**Phone**
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	-
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	-

Early-Stage NSCLC			
Study	**Patients**	**NCT#**	**Sites**
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC.	Stage IB-III NSCLC ALK fusion, ROS1 fusion, NTRK1/2/3 fusion or KRAS G12C (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT)	NCT04302025	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH (RT Group)
1st Line Metastatic NSCLC			
Phase 3 study of vonescimab Versus Pembrolizumab	First line Metastatic NSCLC with High PD-L1 expression	NCT06767514	AMC
Phase 1b/2 study of Telisotuzumab Adizutecan in Combination with Budigalimab	Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536)	NCT06772623	AMC
Study of Response of Bony Metatstases for patients on TKI or systemic treatment	NSCLC with completed molecular testing; receiving standard of care TKI or systemic therapy for actionable driver	NCT03958565	AMC, LT
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors	1L NSCLC PD-L1 TPS ≥ 50%	NCT05533697	AMC (POEMS)
EGFR mutant NSCLC			
LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab in	Metastatic NSCLC EGFR mutant with MET amplification as resistance	NCT05642572	AMC
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC	Metastatic NSCLC with EGFR mutation	NCT05983432	AMC
Immunocore: Phase 1 study of a bispecific T-cell engager to PRAME (HLA-A*02:01) and CD3 + osimertinib	Metastatic NSCLC with EGFR mutation *Note: This trial requires hospitalization and inpatient delivery of study drug for some cycles*	NCT04262466	AMC

Phase 1b/2 study of BG-60366 (EGFR CDAC protein degrader) for EGFRm NSCLC patients	Metastatic NSCLC with EGFR mutation	NCT06685718	AMC
ALK, ROS1, or RET rearranged NSCLC			
NVL-655 EAP: Expanded access program for NVL-665 (novel ALK TKI)	Metastatic NSCLC with ALK	NCT05384626	AMC
NVL-520: Expanded access program for NVL-520 (novel ROS1 TKI)	Metastatic NSCLC with ROS1	NCT05118789	AMC
Phase 1/2 study of amivantamab in metastatic NSCLC with ALK, ROS1 or RET gene fusions	Previously treated advanced NSCLC with ALK, ROS1, or RET gene fusions	NCT05845671	AMC
MET or HER2 altered NSCLC			
SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC	MET exon skip metastatic NSCLC	NCT06031688	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC	HER2 Exon 20 mutated metastatic NSCLC	NCT05983432	AMC
KRAS or BRAF altered NSCLC			
Rev Med: Phase 1 study of RMC-6291 (KRAS G12Ci) + RMC-6236 (KRASi) in KRAS G12C mutant solid tumors	Previously treated metastatic NSCLC with KRAS G12C mutation	NCT06128551	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
2nd Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation			
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload)	Select advanced solid tumors	NCT06384352	AMC (POEMs)
EDDC: Phase 1 study (all-comers) using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	NCT05701527	AMC (POEMs)
2nd Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules			
Immunocore: Phase 1/2 study of IMC-F106C as single agent and in combination with IO in HLA-A*02:01-positive patients with PRAME-positive cancers	HLA-A*02:01-positive patients with PRAME-positive cancers including NSCLC adeno or squamous	NCT04262466	AMC
Zymeworks: Phase 1 study of ZW171, mesothelin-CD3 bispecific T cell engager, in solid tumors. *This trial requires hospitalization and inpatient delivery of study drug for some cycles.*	Previously treated select solid tumors	NCT06523803	AMC
Small Cell Lung Cancer			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung	Small-Cell Lung Cancer	NCT04155034	AMC, HRH
Harpoon: Phase 1 / 2 study of HPN328-4001, Trispecific T-cell activating construct to CD3, HAS, and DLL3. *This trial requires hospitalization and inpatient delivery of study drug for some cycles*	Metastatic SCLC	NCT04471727	AMC

SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC	HER2 Exon 20 mutated metastatic NSCLC and SCLC	NCT05983432	AMC
Mesothelioma and Thymic Malignancies			
AZ Evolve: Phase 3 study of volrustomig (PD1/CTLA4 bispecific) + chemotherapy vs investigators choice	unresectable, untreated mesothelioma	NCT06097728	AMC
Zymeworks: Phase 1 study of ZW171, mesothelin-CD3 bispecific T cell engager, in solid tumors. *This trial requires hospitalization and inpatient delivery of study drug for some cycles.*	Previously treated select solid tumors	NCT06523803	AMC

Cancer Center
NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Satellite Site Contacts		
	Physician Leads	**Nurse Navigators**
CCMC	Scott Kono, MD (Scott.Kono@CUAnschutz.edu)	Lanie Wolff (lanie.wolff@uchealth.org) 720-516-9254
HRH	Elaine Lam, MD (Elaine.Lam@CUAnschutz.edu)	Tera Stewart (Tera.Stewart@CUAnschutz.edu) and Kara Ickler (Kara.Ickler@CUAnschutz.edu)
LT	Corbin Eule, MD (Corbin.Eule@CUAnschutz.edu)	Crystal Stribling (CrystalD.Stribling@uchealth.org)

Common Eligibility Criteria for Clinical Trials	
Performance Status	ECOG 0-1 Karnofsky Performance Status ≥ 60
Age	Age ≥ 18 years (ask for sarcoma trials)
Measurable disease	**Lesions that can be accurately measured in at least one dimension** with a minimum size requirement: • **For CT or MRI scans:** o The lesion must be **≥10 mm** in its longest diameter. o For lymph nodes, the short axis must be **≥15 mm** to be considered measurable. • **For physical exam or clinical measurement:** o The lesion must be **≥10 mm** in its longest dimension and should be measurable with a caliper or ruler. • **For ultrasound:** o Lesions can only be considered measurable if they are confirmed by CT or MRI measurements. **Non-Measurable Lesions:** • Lesions that do not meet the criteria above are classified as **non-measurable.** • Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are **not** considered measurable disease.
Adequate organ and bone marrow function	**Bone marrow:** ANC ≥ 1.5, Hgb ≥ 9.0 (without recent transfusion), platelets ≥ 100 (without recent transfusion). **Hepatic:** AST and ALT < 2 x ULN, bilirubin < 2.0. **Renal:** CrCl ≥ 50 ml/min. **Cardiovascular:** No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months. **Pulmonary:** History of ILD requiring steroids (protocol dependent). **Neurologic:** If brain metastases are present, they must have been treated and not progressing.